CheckMate-73L To Explore Ipilimumab and Nivolumab Combo in Non-Small Cell Lung Cancer Treatment
August 18th 2021The ongoing CheckMate-73L trial seeks to determine if nivolumab plus ipilimumab following nivolumab plus chemoradiation could become the new standard of care in treating non-small cell lung cancer, says Nagla F. Abdel Karim, MD.
Race, Socioeconomic Factors May Impact Survival Outcome in Limited-Stage Small Cell Lung Cancer
July 31st 2021African American, Asian, and Hispanic patients with limited-stage small cell lung cancer displayed superior survival outcomes compared with White patients, indicating that race might be linked with survival in this disease.
Early Study Results Show Novel Combo Therapy May Be Effective in Lung Cancer Subtype
July 14th 2021The preliminary results of an early-phase study of rigosertib combined with nivolumab for the treatment of advanced metastatic KRAS-mutated non-small cell lung cancer are scheduled to be presented at an upcoming medical conference.
FDA Grants Sintilimab/Pemetrexed Review for Frontline Nonsquamous NSCLC
May 19th 2021A biologics license application for sintilimab injection plus pemetrexed and platinum-based chemotherapy for the frontline treatment of patients with nonsquamous non–small cell lung cancer has been accepted for FDA review.